MARKET

NVTA

NVTA

Invitae
NYSE

Real-time Quotes | Nasdaq Last Sale

34.24
+1.02
+3.07%
Pre Market 07:06 07/09 EDT
OPEN
33.59
PREV CLOSE
33.22
HIGH
35.33
LOW
33.40
VOLUME
3.25M
TURNOVER
--
52 WEEK HIGH
35.33
52 WEEK LOW
7.42
MARKET CAP
4.28B
P/E (TTM)
-10.9138
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVTA stock price target is 29.06 with a high estimate of 35.00 and a low estimate of 25.00.

EPS

NVTA News

More
How Fast Is Too Fast Where Fashion Is Concerned?
Bloomberg · 21h ago
XBI: Not Everybody Can Be A Hero
Seeking Alpha - Article · 1d ago
PRESS DIGEST-British Business - July 8
Reuters · 1d ago
PRESS DIGEST- Financial Times - July 8
Reuters · 1d ago
Hedge Funds Aren’t Crazy About InVitae Corporation (NVTA)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of
Insider Monkey · 3d ago
European stocks open higher after Asia bounce
European shares opened higher on Friday after upbeat China data fuelled a bounce in Asian markets, but another record surge in U.S. coronavirus cases checked overall investor optimism. The pan-European STOXX 600 index rose 0.2% to hover near its strongest lev
Reuters · 6d ago
Here's Why Invitae (NVTA) is a Great Momentum Stock to Buy
Does Invitae (NVTA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks · 6d ago
INVITAE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Invitae Corporation - NVTA
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Invitae Corporation (NYSE: NVTA) ("the Company") with ArcherDX in a stock-for-stock transaction. KSF is
Business Wire · 07/01 22:48

Industry

Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About NVTA

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.
More

Webull offers kinds of InVitae Corp stock information, including NYSE:NVTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVTA stock methods without spending real money on the virtual paper trading platform.